Literature DB >> 16039951

The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells.

Susanne Kapitza1, Michael A Jakupec, Maria Uhl, Bernhard K Keppler, Brigitte Marian.   

Abstract

The Ru(III) complex salt KP1019 induced formation of H2O2 in colorectal tumor cells in a dose-dependent way. It also caused DNA-strand breaks if only weakly doubling tail length to 55.87+/-3.97 microm. Both effects were prevented by 5mM N-acetylcysteine (NAC) which also reduced cytotoxicity (IC(50) 55 vs 30 microM without NAC). Induction of apoptosis was shown by loss of mitochondrial membrane potential in 63.4+/-2.1% of the population and by caspase-dependent cleavage of poly-(ADP-ribose)-polymerase (PARP). Both effects were inhibited by NAC which reduced the population with depolarized mitochondrial membranes to 24.1+/-1.2% and prevented PARP-cleavage indicating a central role oxidative stress in KP1019-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16039951     DOI: 10.1016/j.canlet.2005.01.002

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  21 in total

1.  Proteomic analysis of the S. cerevisiae response to the anticancer ruthenium complex KP1019.

Authors:  Laura K Stultz; Alexandra Hunsucker; Sydney Middleton; Evan Grovenstein; Jacob O'Leary; Eliot Blatt; Mary Miller; James Mobley; Pamela K Hanson
Journal:  Metallomics       Date:  2020-06-24       Impact factor: 4.526

2.  In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen.

Authors:  Miljana Momcilovic; Thomas Eichhorn; Jana Blazevski; Harry Schmidt; Goran N Kaluđerović; Stanislava Stosic-Grujicic
Journal:  J Biol Inorg Chem       Date:  2015-02-10       Impact factor: 3.358

Review 3.  Ruthenium-based chemotherapeutics: are they ready for prime time?

Authors:  Emmanuel S Antonarakis; Ashkan Emadi
Journal:  Cancer Chemother Pharmacol       Date:  2010-03-06       Impact factor: 3.333

4.  Synthesis, structure and biological evaluation of ruthenium(III) complexes of triazolopyrimidines with anticancer properties.

Authors:  Marzena Fandzloch; Liliana Dobrzańska; Tomasz Jędrzejewski; Julia Jezierska; Joanna Wiśniewska; Iwona Łakomska
Journal:  J Biol Inorg Chem       Date:  2019-11-18       Impact factor: 3.358

5.  Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339.

Authors:  Petra Heffeter; Katharina Böck; Bihter Atil; Mir Ali Reza Hoda; Wilfried Körner; Caroline Bartel; Ute Jungwirth; Bernhard K Keppler; Michael Micksche; Walter Berger; Gunda Koellensperger
Journal:  J Biol Inorg Chem       Date:  2010-03-11       Impact factor: 3.358

6.  Characterization of the binding sites of the anticancer ruthenium(III) complexes KP1019 and KP1339 on human serum albumin via competition studies.

Authors:  Orsolya Dömötör; Christian G Hartinger; Anna K Bytzek; Tamás Kiss; Bernhard K Keppler; Eva A Enyedy
Journal:  J Biol Inorg Chem       Date:  2012-10-18       Impact factor: 3.358

7.  Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR.

Authors:  Naniye Cetinbas; Michael I Webb; Joshua A Dubland; Charles J Walsby
Journal:  J Biol Inorg Chem       Date:  2009-08-26       Impact factor: 3.358

8.  Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.

Authors:  L Brescacin; A Masi; G Sava; A Bergamo
Journal:  J Biol Inorg Chem       Date:  2015-09-14       Impact factor: 3.358

Review 9.  Unusual DNA binding modes for metal anticancer complexes.

Authors:  Ana M Pizarro; Peter J Sadler
Journal:  Biochimie       Date:  2009-04-01       Impact factor: 4.079

10.  Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion.

Authors:  A Bergamo; A Masi; M A Jakupec; B K Keppler; G Sava
Journal:  Met Based Drugs       Date:  2009-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.